Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Saskatchewan Providing Drug Coverage for Saskatoon Siblings

Released on November 3, 2015

After additional review and consultation, the provincial government has made a decision to provide interim drug coverage for three Saskatoon siblings who have Morquio syndrome.  The province will cover the cost of Vimizim for these children for a period of one year to allow for an assessment of its effectiveness.

“After hearing the challenges faced by this family, I asked the Ministry of Health to revisit the initial decision and seek additional clinical expertise,” Health Minister Dustin Duncan said.  “While uncertain of its effectiveness, the specialists we consulted indicated a trial period could establish if this drug may provide any benefit to these children.”

There will be opportunity for assessment of its effectiveness during the period of the one year trial.

Saskatchewan will continue to collaborate with other provinces and territories on a consistent, national approach to review expensive drugs for rare diseases.  Any further decision to provide coverage for Vimizim will be made on a case-by-case basis, and will rely on out-of-province specialist recommendations.

-30-

For more information, contact:

Tyler McMurchy
Health
Regina
Phone: 306-787-4083
Email: tyler.mcmurchy@health.gov.sk.ca
Cell: 306-537-3594

We need your feedback to improve saskatchewan.ca. Help us improve